Supplements

Nabiximols improves sleep disruption in multiple sclerosis patients

A systematic review and meta-analysis of 25 studies (2949 patients) found that nabiximols significantly reduced sleep disruption in MS patients (MD = -15.75; 95% CI = (-22.02)-(-9.49)). The evidence certainty was low to very low, and findings are considered exploratory.

1 min read•Updated Jul 29, 2026•0 RCTs•1 Meta-analyses•View structured evidence →
Evidence Score49/100
Human RCT☆☆☆☆☆
Meta-analysis★★★☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Nabiximols improves sleep disruption in multiple sclerosis patients The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 49/100 (low).

The Claim

Nabiximols improves sleep disruption in multiple sclerosis patients

This conclusion is most relevant to: Adult patients with multiple sclerosis (MS) with moderate to severe spasticity.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Nabiximols in Multiple Sclerosis: Beyond Spasticity-An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes. (Medical sciences (Basel, Switzerland), 2026) —

How It Works

The proposed biological pathway:

  • ▸Nabiximols binds to cannabinoid receptors (CB1 and CB2) in the central nervous system
  • ▸Modulation of neurotransmitter release reduces spasticity and associated symptoms
  • ▸Improved spasticity and pain may lead to better sleep quality
  • ▸Result: Reduced sleep disruption in MS patients

Who Might Benefit

Evidence fit by population:

  • ▸Adult patients with multiple sclerosis (MS) with moderate to severe spasticity

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Evidence certainty was low to very low
  • ▸Findings are exploratory and not definitive
  • ▸Time-dependency of effects was not significant

Frequently Asked Questions

What is nabiximols?▼

Nabiximols is a standardized extract of Cannabis sativa approved as add-on therapy for moderate to severe spasticity in multiple sclerosis.

How much does nabiximols improve sleep disruption?▼

The meta-analysis reported a mean difference of -15.75 (95% CI: -22.02 to -9.49) for sleep disruption, indicating significant improvement.

Is this evidence strong enough to recommend nabiximols for sleep problems in MS?▼

No, the evidence certainty was low to very low, so these findings are exploratory and not sufficient for clinical recommendations.

What other symptoms did nabiximols improve in this study?▼

Beyond sleep disruption, nabiximols also improved spasm quality, bladder function, and gait function in MS patients.

References

  1. 1.Kleiner D, Horváth IL, Mátis D, Nagy R, Gergő D, Lugosi K, Fazekas G, Fehérvári P, Hegyi P, Csupor D. “Nabiximols in Multiple Sclerosis: Beyond Spasticity-An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes..” Medical sciences (Basel, Switzerland), 2026. PMID: 42506315 DOI: 10.3390/medsci14030346
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.